anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A prospective randomized controlled study: Patients undergoing posterior spinal fusion will be randomized to a standard postoperative dressing versus an incisional VAC dressing. Both groups will have hematocrit, total lymphocyte count, and albumin checked preoperatively to assess nutritional status, drawn at the same time as standard preoperative labs during history and physical visit. Both groups will undergo standard wound closure and dressing application before breaking the sterile field. The incisional VAC group will undergo placement of an Adaptic dressing over the incision. A standard VAC sponge will be placed and secured with adhesive dressing, and a suction tube will be connected to a VAC machine set to 75 mmHg of continuous suction. The incisional VAC will be left in place for 72 hours postoperatively. Remainder of postoperative care will follow our standard posterior spinal fusion protocol and will be identical in both groups. Patients will be followed for a minimum of 2 years postoperatively.
PURPOSE:An adhesive for dental purposes that contains an organic solvent boiling in a certain range of temperature and a thermoplastic polyhydroxyehter at a specific ratio, thus allowing a polysulfone resin for dental purposes and an acrylic resin for dental purposes to adhere to each other confirmly. CONSTITUTION:The objective adhesive contains 100pts.wt. of an organic solvent boiling at 30-250 deg.C such as methyl ehtyl ketone, N-methylpyrrolidone or dimethylformamide and 0.3-40pts.wt. of a thermoplastic polyhydroxy ether (which is obtained by polymerization of equimolar amounts of a divalent phenol and an epoxide bearing 1-2 epoxide groups). When needed, in addition, 0.1-10 pts.wt. of a coupling agent such as gamma-(2-aminoethyl)aminopropyltrimetoxysilane may be added.
BACKGROUND: The Paris classification categorises colorectal polyp morphology. Interobserver agreement for Paris classification has been assessed at optical colonoscopy (OC) but not CT colonography (CTC). We aimed to determine the following: (1) interobserver agreement for the Paris classification using CTC between radiologists; (2) if radiologist experience influenced classification, gross polyp morphology, or polyp size; and (3) the extent to which radiologist classifications agreed with (a) colonoscopy and (b) a combined reference standard.
METHODS: Following ethical approval for this non-randomised prospective cohort study, seven radiologists from three hospitals classified 52 colonic polyps using the Paris system. We calculated interobserver agreement using Fleiss kappa and mean pairwise agreement (MPA). Absolute agreement was calculated between radiologists; between CTC and OC; and between CTC and a combined reference standard using all available imaging, colonoscopic, and histopathological data.
RESULTS: Overall interobserver agreement between the seven readers was fair (Fleiss kappa 0.33; 95% CI 0.30-0.37; MPA 49.7%). Readers with < 1500 CTC experience had higher interobserver agreement (0.42 (95% CI 0.35-0.48) vs. 0.33 (95% CI 0.25-0.42)) and MPA (69.2% vs 50.6%) than readers with ≥ 1500 experience. There was substantial overall agreement for flat vs protuberant polyps (0.62 (95% CI 0.56-0.68)) with a MPA of 87.9%. Agreement between CTC and OC classifications was only 44%, and CTC agreement with the combined reference standard was 56%.
CONCLUSION: Radiologist agreement when using the Paris classification at CT colonography is low, and radiologist classification agrees poorly with colonoscopy. Using the full Paris classification in routine CTC reporting is of questionable value.
CLINICAL RELEVANCE STATEMENT: Interobserver agreement for radiologists using the Paris classification to categorise colorectal polyp morphology is only fair; routine use of the full Paris classification at CT colonography is questionable.
KEY POINTS: • Overall interobserver agreement for the Paris classification at CT colonography (CTC) was only fair, and lower than for colonoscopy. • Agreement was higher for radiologists with < 1500 CTC experience and for larger polyps. There was substantial agreement when classifying polyps as protuberant vs flat. • Agreement between CTC and colonoscopic polyp classification was low (44%).
Behavioral: Structured web- and mobile-based intervention with Youth COMPASS program to support adolescents' well-being, career preparation and life-control and subsequently support successful transition to upper secondary education. The Youth COMPASS is the five-week online program according to principles of Acceptance and Commitment Therapy aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal life (weeks 4-5). The participants in this condition receive weekly online support and feedback from their individually assigned coach. In addition, they meet their coach twice in the face-to-face meetings. The aim of the meetings is to increase adolescents' internal motivation and thereby participation in the program.
Nateglinide is highly bound to plasma proteins (98%), mainly albumin. In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding. Similarly, nateglinide had no influence on the serum protein binding of propranolol, glyburide, nicardipine, warfarin, phenytoin, acetylsalicylic acid and tolbutamide in vitro. However, prudent evaluation of individual cases is warranted in the clinical setting.

Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents, guanethidine, and CYP2C9 inhibitors (e.g., fluconazole, amiodarone, miconazole, oxandrolone) may potentiate the hypoglycemic action of nateglinide and other oral antidiabetic drugs.

Certain drugs including thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, rifampin, phenytoin and dietary supplements (St. John’s wort) may reduce the hypoglycemic action of nateglinide and other oral antidiabetic drugs. Somatostatin analogues may potentiate or attenuate the hypoglycemic action of nateglinide.

When these drugs are administered to or withdrawn from patients receiving nateglinide, the patient should be observed closely for changes in glycemic control.
<P>PROBLEM TO BE SOLVED: To photopolymerize and cure a dental photo-curable composition with light focused on such a region or depth that the light can not reach and a region where the optical strength is required without attenuating the light till the light reaches a target region by combining the dental photo-curable composition with a fiber post including optical fibers whose irradiation regions are not limited.  <P>SOLUTION: The fiber post including optical fiber has the optical fibers transmitting the light which are disposed approximately at the center of the fiber post, and inorganic and/or organic fibers disposed parallel are integrated with the optical fibers. The fiber post transmits at least the light of 350-520 nm wavelength. The light is emitted from a light emission part as the light source with the output of 10-10,000 mW, or more preferably, 100-6,000 mW. As the light source, such light sources as applied in the dentistry, for example, a halogen lamp, a xenon lamp, or a light emitting diode lamp, can be used.  <P>COPYRIGHT: (C)2010,JPO&INPIT
PURPOSE:An antiallergic containing a flavone glycoside as an active ingredient. CONSTITUTION:An antiallergic containing a compound shown by the formula contained in an extracted essence of Kalanchoe pinnatum belonging to the family Crassulaceae. The compound shown by the formula is obtained by extracting the whole weed of Kalanchoe pinnatum with an extracting solvent such as a water-alcohol mixed solvent, an alcohol, etc., and subjecting the prepared extracted essence to a conventional means (e.g., partition chromatography among various solvents, adsorption chromatography, etc.) used in purifi-cation and isolation of plant components. It is effective against allergic asthma, hay asthma, allergic conjunctivities, allergic rhinitis, etc. It is applied by oral administration, inhalation, external use, intravenous injection, intramuscular injection, rectal administration, etc. A dose is 5-100 mg/kg.
Cancer is a mysterious disease. Among other alterations, tumor cells, importantly, have metabolic modifications. A well-known metabolic modification commonly observed in cancer cells has been termed the Warburg effect. This phenomenon is defined as a high preference for glucose uptake, and increased lactate production from that glucose, even when oxygen is readily available. Some anti-cancer drugs target the proposed Warburg effect, and some dietary regimens can function similarly. However, the most suitable dietary strategies for treating particular cancers are not yet well understood. The aim of this review was to describe findings regarding the impact of various proposed dietary regimens targeting the Warburg effect. The evidence suggests that combining routine cancer therapies with diet-based strategies may improve the outcome in treating cancer. However, designing individualized therapies must be our ultimate goal.
INTRODUCTION: Concurrent obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease (COPD) are referred to as COPD-OSA overlap. We investigated the prevalence and clinical significance of COPD-OSA overlap in the general population of South Korea.
METHODS: Data were obtained from the 2019 Korea National Health and Nutrition Examination Survey. Participants ≥40 years of age with complete STOP-Bang questionnaire and spirometry data were included. OSA was presumed in individuals with a STOP-Bang score of ≥3. COPD was determined using forced expiratory volume at 1 s/forced vital capacity <0.7. Participants were classified on the basis of the STOP-Bang score and spirometry findings. Clinical characteristics, comorbidities, and quality of life (using the EuroQoL 5-dimension instrument) were compared between the overlap group and COPD-alone or OSA-alone groups.
RESULTS: Among the 3157 participants, 6.9 % demonstrated COPD-OSA overlap. Individuals with OSA alone and COPD alone were 31.8 % and 5.2 %, respectively. The overlap group included more males, ever smokers, and frequent alcohol drinkers than the COPD- or OSA-alone groups. The overlap group had more diagnoses of hypertension, diabetes, and stroke than the COPD-alone group. The risk of anxiety/depression was approximately 2.5 times higher in the overlap group than in the COPD-alone group. COPD-OSA overlap was a significant risk factor for anxiety/depression after adjusting for age, sex, household income, and education levels.
CONCLUSION: COPD-OSA overlap is not rare within the general population of South Korea. Patients with overlap showed more comorbidities and higher levels of anxiety/depression than those in the COPD-alone group.
A denture care kit may comprise a denture adhesive composition, a container, and information for use. The denture adhesive composition may comprise a safe and effective adhesive amount of a denture adhesive component, wherein the denture adhesive composition may have a viscosity of from about 5 to about 80 Brookfield. The container may be used for holding and dispensing the denture adhesive composition. The container may comprise a nozzle. The nozzle may have a tip diameter of from about 80 mils to about 120 mils, and a length from about 10 mm to about 25 mm. Information for use for decreasing food entrapment may be used to instruct the denture wearer to apply the denture adhesive composition as a continuous peripheral bead along at least one of the back quarter portion, the back half portion, the back three-quarters portion, the front quarter portion, the front half portion, the front three-quarters portion, or the entire periphery of an upper and/or lower denture.
This is a feasibility pilot study project assessing the presence of compassion fatigue in clinical research nurses (cohort 1) and bone marrow transplant nurses (cohort 2). A survey will be completed by participants prior to and after an educational presentation. The intervention includes the risk factors, signs and symptoms, and interventions on compassion fatigue. The survey will be completed prior to the education, immediately following the education, one month following the education and two months following the education. A final survey will be implemented for the cohort 2 only. The objective of this concluding analysis is to gather data relative to CF and coping mechanisms.
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology, specifically to a method for conjugating a recombinant constant fragment of a human immunoglobulin heavy chain (Fc) and a peptoid analogue of autoantigen MOG35-55 (AMogP3). Chemical conjugation of Fc with a bifunctional cross-linker linker NHS-PEG2-maleimide is carried out at a ratio of reagents of 1:10 and an optimum length of the cross-linking reagent of 17.6 angstroms. Obtained fragment Fc-linker is purified from unreacted linker by means of desalting chromatographic column. Chemical conjugation of peptide AMogP3 carrying a free thiol group and a Fc-linker fragment are carried out at the ratio of reagents Fc-linker: peptoid = 1:2. Fc-linker: peptoid mixture is concentrated with cooling to 4 °C. Obtained bifunctional agent Fc-linker-peptoid module AMogP3 is purified from unreacted peptoid AMogP3 by gel filtration chromatography. Duration of one complete cycle of extraction and purification is 3 hours. Output of target product is 61.2 %. Invention improves efficiency of conjugation of peptoid analogue of autoantigen MOG35-55 with a constant domain of a heavy chain of human immunoglobulin.EFFECT: prepared conjugate is suitable for multiple sclerosis therapy.1 cl, 4 dwg, 1 tbl, 4 ex
Insulin human is a short-acting human insulin. It is a polypeptide hormone and is produced by recombinant DNA technology, utilizing Pichia pastoris (a yeast) as the production organism. Insulin human is regular human insulin and has the empirical formula C257H383N65O77S6 and a molecular weight of 5808.

Figure 1: Structural formula of Insulin Human

MYXREDLIN (insulin human) in 0.9% sodium chloride injection for intravenous use is a sterile, preservative-free, nonpyrogenic, clear, aqueous, and colorless solution supplied in a 100 mL GALAXY single-dose container. MYXREDLIN contains 100 units of insulin human in 100 milliliters of 0.9% sodium chloride injection. Each milliliter of solution contains 1 unit Insulin Human, USP; 0.412 mg Dibasic Sodium Phosphate Anhydrous, USP; 0.29 mg Monobasic Sodium Phosphate Monohydrate, USP; 9 mg Sodium Chloride, USP; and Water for Injection, USP. The pH range is 6.5-7.2.
PURPOSE: To stabilize a hydrated lipid thin phase or a liposome-type micell by preparing the hydrated lipid thin phase or the liposome in the presence of atelocollagen-glycosaminoglycans. CONSTITUTION: An atelocollagen soln. and a soln. of glycosaminoglycans are independently prepared and then, the atelocollagen soln. is mixed with the soln. of glycosaminoglycans. Then, a hydrated lipid thin phase or liposome is prepared in the presence of the homogeneous soln. of the atelocollagen- glycosaminoglycans. By this method, the stabilization of the hydrated lipid thin phase, especially of the liposome is enhanced and the obtd. material is used for a pharmaceutical compsn. or a cosmetic compsn.
This research aims to study the effect of magnetic nanoparticles of Fe3O4 (MNP Fe3O4) containing gambogic acid (GA-MNP Fe3O4) on colorectal cancer (CRC). MNP Fe3O4 enhanced the antitumor effect of GA by inhibiting the malignant behavior of CRC cells. RORB was a target of GA, and GA activated RORB expression to inhibit metastasis of CRC. Knockdown of RORB impaired the effect of GA-MNP Fe3O4 on CRC metastasis. EMILIN1 was a target of RORB, and RORB promoted transcription of EMILIN1. Overexpression of EMILIN1 reversed the effect of knockdown of RORB on GA-MNP Fe3O4 and inhibited metastasis in CRC. These findings revealed that MNP Fe3O4 enhanced the antitumor effect of GA and activated RORB to promote EMILIN1 transcription and inhibit CRC metastasis.
Naproxen is a proprionic acid derivative related to the arylacetic acid group of nonsteroidal anti-inflammatory drugs.

The chemical names for naproxen and naproxen sodium are (S)-6-methoxy-α-methyl-2-naphthaleneacetic acid and (S)-6-methoxy-α-methyl-2-naphthaleneacetic acid, sodium salt, respectively. Naproxen and naproxen sodium have the following structures, respectively:

Naproxen has a molecular weight of 230.26 and a molecular formula of C14H14O3. Naproxen sodium has a molecular weight of 252.23 and a molecular formula of C14H13NaO3.

Naproxen is an odorless, white to off-white crystalline substance. It is lipid-soluble, practically insoluble in water at low pH and freely soluble in water at high pH. The octanol/water partition coefficient of naproxen at pH 7.4 is 1.6 to 1.8. Naproxen sodium is a white to creamy white, crystalline solid, freely soluble in water at neutral pH.

NAPROXEN (naproxen tablets) is available as yellow tablets containing 250 mg of naproxen, pink tablets containing 375 mg of naproxen and yellow tablets containing 500 mg of naproxen for oral administration. The inactive ingredients are croscarmellose sodium, iron oxides, povidone and magnesium stearate.

EC-NAPROXEN (naproxen delayed-release tablets) is available as enteric-coated white tablets containing 375 mg of naproxen and 500 mg of naproxen for oral administration. The inactive ingredients are croscarmellose sodium, povidone and magnesium stearate. The enteric coating dispersion contains methacrylic acid copolymer, talc, triethyl citrate, sodium hydroxide and purified water. The dissolution of this enteric-coated naproxen tablet is pH dependent with rapid dissolution above pH 6. There is no dissolution below pH 4.

NAPROXEN SODIUM (naproxen sodium tablets) is available as blue tablets containing 275 mg of naproxen sodium and NAPROXEN SODIUM DS (naproxen sodium tablets) is available as dark blue tablets containing 550 mg of naproxen sodium for oral administration. The inactive ingredients are magnesium stearate, microcrystalline cellulose, povidone and talc. The coating suspension for the NAPROXEN SODIUM 275 mg tablet may contain hydroxypropyl methylcellulose 2910, Opaspray K-1-4210A, polyethylene glycol 8000 or Opadry YS-1-4215. The coating suspension for the NAPROXEN SODIUM DS 550 mg tablet may contain hydroxypropyl methylcellulose 2910, Opaspray K-1-4227, polyethylene glycol 8000 or Opadry YS-1-4216.
The investigators will prescribe isocaloric diets equaling the estimated energy requirements of the Institute of Medicine. Participants on the LCD intervention will consume 25-35% of total daily intake from carbohydrates, 45-65% from fat and 10-30% from protein.
PURPOSE: The purpose of this paper is to compile and present all of the reported vascular complications that resulted from common non-vascular abdominal procedures in the literature. Non-vascular procedures include, though are not limited to, percutaneous abscess/fluid collection drainage (PAD), percutaneous nephrostomy (PN), paracentesis, percutaneous transhepatic cholangiography (PTC)/percutaneous biliary drainage (PBD), percutaneous biliary stone removal, and percutaneous radiologic gastrostomy (PG)/percutaneous radiologic gastrojejunostomy (PG-J). By gathering this information, radiologists performing these procedures can be aware of the associated vascular injuries, as well as take steps to minimize risks.
METHODS: A literature review was conducted using the PubMed database to catalog relevant articles, published in the year 2000 onward, in which an iatrogenic vascular complication occurred from the following non-vascular abdominal procedures: PAD, PN, paracentesis, PTC/PBD, percutaneous biliary stone removal, and PG/PG-J. Biopsy and tumor ablation were deferred from this article.
RESULTS: 214 studies met criteria for analysis. 28 patients died as a result of vascular complications from the analyzed non-vascular abdominal procedures. Vascular complications from paracentesis were responsible for 19 patient deaths, followed by four deaths from PTC/PBD, three from biliary stone removal, and two from PG.
CONCLUSION: Despite non-vascular percutaneous abdominal procedures being minimally invasive, vascular complications still can arise and be quite serious, even resulting in death. Through the presentation of vascular complications associated with these procedures, interventionalists can improve patient care by understanding the steps that can be taken to minimize these risks and to reduce complication rates.
An ephedrannin K is provided to suppress the activation of tyrosinase and melanogenesis. An ephedrannin K is denoted by the chemical formula I. The compound has anti-inflammation activity. A composition for treating inflammatory diseases comprises the compound as an active ingredient. The inflammatory disease is disease selected among asthma, osteoporosis, septic shock, hemorrhagic shock, multiple sclerosis, rheumatoid arthritis, ulcerative colitis, arteriosclerosis, alzheimer, asthma and Huntington`s disease. The compound has the activation of tyrosinase inhibition and melanogenesis suppression.
PCT No. PCT/JP93/01780 Sec. 371 Date Aug. 8, 1994 Sec. 102(e) Date Aug. 8, 1994 PCT Filed Dec. 8, 1993 PCT Pub. No. WO94/13253 PCT Pub. Date Jun. 23, 1994A hair dye consisting of an anti-hair antibody immobilized on a high bulky coloring material. The coloring material may be a coloring substance such as an inorganic pigment, water-soluble coloring matter, or water-insoluble coloring matter, or a composite of the coloring substance and a macromolecular carrier. Since it provides a good and strong coloring capability specific to hair, the hair dye of the present invention will neither stain the skin nor cause skin irritation. Further, the touch and feel of the hair will be improved.
To describe the pharmacokinetics/pharmacodynamics (PK/PD) of a 2 h infusion of ceftazidime-avibactam (CAZ-AVI) in critically ill patients with augmented renal clearance (ARC). A retrospective review of all critically ill patients with ARC who were treated with CAZ-AVI between August 2020 and May 2023 was conducted. Patients whose 12-h creatinine clearance prior to CAZ-AVI treatment and steady-state concentration (Css) of CAZ-AVI were both monitored were enrolled. The free fraction (fCss) of CAZ-AVI was calculated from Css. The joint PK/PD targets of CAZ-AVI were considered optimal when a Css/minimum inhibitory concentration (MIC) ratio for CAZ ≥4 (equivalent to 100% fT > 4 MIC) and a Css/CT ratio of AVI >1 (equivalent to 100% fT > CT 4.0 mg/L) were reached simultaneously, quasioptimal when only one of the two targets was reached, and suboptimal when neither target was reached. The relationship between PK/PD goal achievement, microbial eradication and the clinical efficacy of CAZ-AVI was evaluated. Four patients were included. Only one patient achieved optimal joint PK/PD targets, while the other three reached suboptimal targets. The patient with optimal PK/PD targets achieved microbiological eradication, while the other three patients did not, but all four patients achieved good clinical efficacy. Standard dosages may not enable most critically ill patients with ARC to reach the optimal joint PK/PD targets of CAZ-AVI. Optimal drug dose adjustment of CAZ-AVI in ARC patients requires dynamic drug concentration monitoring.